Event snippet :
top of page
  • Writer's pictureRachel O'Reilly

Aalto Bio Reagents Launches Lysis Buffer Reagent for COVID-19 testing.

Dublin, Ireland – May 1st, 2020 – Aalto Bio Reagents Ltd., Ireland’s leading supplier of critical raw materials and reagents for diagnostic tests, today announced the availability of its first RNA lysis buffer reagent for the pre-treatment of COVID 19 samples prior to testing.

Aalto Bio was contacted by Ireland's Health Service Executive (HSE) in March 2020 to see if the company could refocus their manufacturing and development capabilities to provide a RNA lysis buffer which would be used by hospitals and laboratories for COVID-19 testing. Within just 4 weeks of being contacted, the first bulk order was shipped to the National Virus Reference Laboratory in UCD where most of Ireland's testing is being carried out.

The volume of PCR tests being carried out for COVID-19 in Ireland, and indeed across the world at present, is such that manufacturers simply cannot produce the volume of reagents required.This essential RNA Lysis buffer was produced by Aalto Bio due to the unavailability of similar reagents from other manufacturers in Europe.

“At Aalto Bio, we were happy to assist the HSE by producing this critical reagent to help alleviate some of the pressure that has been brought on the system by COVID-19. As the HSE continues to expand on its testing capabilities we expect the demand for critical raw material such as ours to grow, and we are prepared to offer our services when needed. As a wholly owned Irish diagnostics company we are proud to be able to contribute towards the testing regime of COVID-19. “stated Philip Noone, CEO, Aalto Bio Reagents.

About Aalto Bio Reagents

Founded in 1978, Aalto Bio Reagents is a leading developer and provider of raw materials to the in-vitro diagnostics industry and to research laboratories globally. We serve the largest multinational companies in our industry with a broad range of purified human proteins; monoclonal and polyclonal antibodies; fungal, parasitic, bacterial and viral antigens; and disease state plasma for in-vitro diagnostic application. Since the company's inception, we have built strong working relationships with our clients who trust us to provide them with the highest quality raw materials to meet the exacting standards of their own product development requirements. Headquartered in Dublin, Ireland, the company is rapidly expanding both its product portfolio and customer base.


Tel: +353-1-4900685

Email: info@aaltobioreagents.com

418 views0 comments


bottom of page